Navigation Links
Ready-To-Use IHC Bluing Reagent from Bethyl Laboratories

ProductsReady-To-Use IHC Bluing Reagent from Bethyl Laboratories
Company Bethyl Laboratories
Item Ready-To-Use IHC Bluing Reagent
Price $40.00
Description Bethyl Laboratories Ready-To-Use IHC Bluing Reagent is used following IHC hematoxylin counterstaining with immunohistochemical procedures.
Shelf-Life: 1 year from date of receipt
Info Bethyl LaboratoriesBethyl Laboratories
Bethyl Laboratories
P.O. Box 850
Montgomery, TX 77356
Customer Service: 800-338-9579
Fax Number: 936-597-6105
Web Site: http://www.bethyl.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Cleland’s Reagent from Calbiochem
2. Cleland’s Reagent, ULTROL® Grade from Calbiochem
3. GenomONE-Neo EX HVJ-E 4 vial(s) Transfection Reagents from Cosmo Bio Co., Ltd.
4. Cleland’s Reagent, Molecular Biology Grade from Calbiochem
5. Cleland’s Reagent from Calbiochem
6. Cleland’s REDUCTACRYL™ Reagent from Calbiochem
7. Human and Mouse RAR Neutralizing Peptide from ABR-Affinity BioReagents
8. Rat rab 3D Neutralizing Peptide from ABR-Affinity BioReagents
9. Rat SAP97 Neutralizing Peptide from ABR-Affinity BioReagents
10. Rat SCAMP 5 Neutralizing Peptide from ABR-Affinity BioReagents
11. Bovine rhodopsin Neutralizing Peptide from ABR-Affinity BioReagents
... Ambions MAXIscript In Vitro Transcription Kits ... 1 x 10 9 cpm/g. High ... in ribonuclease protection assays, in situ hybridization, ... be used for the synthesis of modest ...
Mouse H60 Allophycocyanin MAb (Clone 205326) ENTREZ GeneID: 15101...
... 250 ul (125 precipitations). ... easy pellet location.Efficient precipitation ... inert, compatible with most ... protocol. Category: DNA/RNA Synthesis ...
... for monitoring Aldolase tests. 2 levels ... targeted manufacturing values at 4 ± ... IU/L. 30-day shelf life once ... Level 1: 3 x 3 ml; ...
Biology Products:
(Date:3/3/2015)... FOREST, Calif. , March 3, 2015 ... the leading provider of advanced cryogenic logistics ... markets including immunotherapies, stem cells, cell lines, ... and reproductive medicine, today announced the expansion ... Cancer Research Centers, ("Fred Hutch") Clinical ...
(Date:3/2/2015)... , March 2, 2015  Businesses have ... Data protection company Tharon Rankins Enterprises has announced ... provides an ultra-safe way for businesses to protect ... financial transactions. Beconux is a ... Rankins Enterprises. Functioning similarly to an ATM machine, ...
(Date:2/25/2015)... LITTLE ROCK, Ark. , Feb. 25, 2015 ... of software and billing in the Health and ... software as well as to MYiCLUBonline.  The latest ... MYiCLUBonline and the inclusion of cardless check-in via ... demonstrated for the first time through interactive displays ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Personal Data Protection Company Launches New Product 2ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
... PASADENA, Calif.A California Institute of Technology (Caltech)-led ... first proof that a targeted nanoparticleused as an ... bloodstreamcan traffic into tumors, deliver double-stranded small interfering ... gene using a mechanism known as RNA interference ...
... A potential new energy source so controversial that people once ... by the mainstream scientific community. That,s the conclusion of the ... topic "cold fusion" being held here for the ... National Meeting of the American Chemical Society (ACS). "Years ...
... , , Michael M. Graham, Ph.D., M.D., president, ... chair, SNM Medical Isotope Task Force, Jeffrey P. Norenberg, ... member, SNM Medical Isotope Task Force, WHEN:,Immediately ... over a two-week period when cancer, heart and brain ...
Cached Biology News:Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles 2Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles 3Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles 4'Cold fusion' moves closer to mainstream acceptance 2'Cold fusion' moves closer to mainstream acceptance 3'Cold fusion' moves closer to mainstream acceptance 4
(Date:3/4/2015)... 4, 2015  Brooklyn residents now have a new ... pain and injuries. Nunzio Saulle , M.D., a ... of his NJS Physical Medicine and Rehabilitation (PM&R) practice ... March 5, 2015. Health Plus Management, LLC is managing ... at 1178 Flatbush Avenue. This new PM&R practice will ...
(Date:3/4/2015)... /CNW/ - Resverlogix Corp. (TSX:RVX) (the "Company") today ... research program with Emerald Logic, a leader ... Technology (FACET), Emerald Logic analyzed Resverlogix,s complete ... each of 798 patients who participated in ... SUSTAIN and ASSURE. The objective of this ...
(Date:3/4/2015)... Pa. , March 4, 2015 /PRNewswire/ ... services and technology provider, today announced that ... 10 countries convened at its annual European ... to discuss the use of ... challenges. BioClinica,s eClinical technologies include: the Microsoft ...
(Date:3/4/2015)... Lancée par l,Assistance ... en décembre 2011, l,étude collaborative française randomisée ... compare   l es microsphères en résine ... le carcinome hépatocellulaire avancé, a recruté plus de ...   ; les résultats sont attendus fin 2016. ...
Breaking Biology Technology:NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6